Pesquisa | Biblioteca Virtual em Saúde

1.

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.

Tewari, Krishnansu S; Sill, Michael W; Birrer, Michael J; Penson, Richard T; Huang, Helen; Moore, David H; Ramondetta, Lois M; Landrum, Lisa M; Oaknin, Ana; Reid, Thomas J; Leitao, Mario M; Michael, Helen E; Monk, Bradley J.

Gynecol Oncol ; 171: 141-150, 2023 04.

Artigo em Inglês | MEDLINE | ID: mdl-36898292

2.

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Tewari, Krishnansu S; Sill, Michael W; Penson, Richard T; Huang, Helen; Ramondetta, Lois M; Landrum, Lisa M; Oaknin, Ana; Reid, Thomas J; Leitao, Mario M; Michael, Helen E; DiSaia, Philip J; Copeland, Larry J; Creasman, William T; Stehman, Frederick B; Brady, Mark F; Burger, Robert A; Thigpen, J Tate; Birrer, Michael J; Waggoner, Steven E; Moore, David H; Look, Katherine Y; Koh, Wui-Jin; Monk, Bradley J.

Lancet ; 390(10103): 1654-1663, 2017 Oct 07.

Artigo em Inglês | MEDLINE | ID: mdl-28756902

3.

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.

Moore, Kathleen N; Java, James J; Slaughter, Katrina N; Rose, Peter G; Lanciano, Rachelle; DiSilvestro, Paul A; Thigpen, J Tate; Lee, Yi-Chun; Tewari, Krishnansu S; Chino, Junzo; Seward, Shelly M; Miller, David S; Salani, Ritu; Moore, David H; Stehman, Frederick B.

Gynecol Oncol ; 143(2): 294-301, 2016 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-27542967

4.

ACR Appropriateness Criteria® Adjuvant Management of Early-Stage Endometrial Cancer.

Wahl, Andrew O; Gaffney, David K; Jhingran, Anuja; Yashar, Catheryn M; Biagioli, Matthew; Elshaikh, Mohamed A; Jolly, Shruti; Kidd, Elizabeth; Lee, Larissa J; Li, Linna; Moore, David H; Rao, Gautam G; Williams, Ned L; Small, William.

Oncology (Williston Park) ; 30(9): 816-22, 2016 09 15.

Artigo em Inglês | MEDLINE | ID: mdl-27633412

5.

ACR Appropriateness Criteria® Adjuvant Therapy in Vulvar Cancer.

Jolly, Shruti; Soni, Payal; Gaffney, David K; Biagioli, Matthew; Elshaikh, Mohamed A; Jhingran, Anuja; Kidd, Elizabeth; Lee, Larissa J; Li, Linna; Moore, David H; Rao, Gautam G; Wahl, Andrew O; Williams, Ned L; Yashar, Catheryn M; Small, William.

Oncology (Williston Park) ; 29(11): 867-72, 874-5, 2015 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-26568534

6.

Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study.

Chase, Dana M; Huang, Helen Q; Wenzel, Lari; Cella, David; McQuellon, Richard; Long, Harry J; Moore, David H; Monk, Bradley J.

Gynecol Oncol ; 125(2): 315-9, 2012 May.

Artigo em Inglês | MEDLINE | ID: mdl-22307062

7.

A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study.

Moore, David H; Ali, Shamshad; Koh, Wui-Jin; Michael, Helen; Barnes, Mack N; McCourt, Carolyn K; Homesley, Howard D; Walker, Joan L.

Gynecol Oncol ; 124(3): 529-33, 2012 Mar.

Artigo em Inglês | MEDLINE | ID: mdl-22079361

8.

Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.

Moore, David H; Tian, Chunqiao; Monk, Bradley J; Long, Harry J; Omura, George A; Bloss, Jeffrey D.

Gynecol Oncol ; 116(1): 44-9, 2010 Jan.

Artigo em Inglês | MEDLINE | ID: mdl-19853287

9.

Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).

Tewari, Krishnansu S; Sill, Michael W; Monk, Bradley J; Penson, Richard T; Moore, David H; Lankes, Heather A; Ramondetta, Lois M; Landrum, Lisa M; Randall, Leslie M; Oaknin, Ana; Leitao, Mario M; Eisenhauer, Eric L; DiSilvestro, Paul; Van Le, Linda; Pearl, Michael L; Burke, James J; Salani, Ritu; Richardson, Debra L; Michael, Helen E; Kindelberger, David W; Birrer, Michael J.

Mol Cancer Ther ; 19(11): 2363-2370, 2020 11.

Artigo em Inglês | MEDLINE | ID: mdl-32847980

10.

Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one?

Moore, David H.

Gynecol Oncol ; 113(3): 379-83, 2009 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-19232700

11.

Reflections on vulvar tumors, lymphatic drainage, and sentinel lymph node biopsy.

Moore, David H.

Gynecol Oncol ; 128(2): 153-4, 2013 Feb.

Artigo em Inglês | MEDLINE | ID: mdl-23337403

12.

Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies.

Plaxe, Steven C; Brooks, Sandra E; Tian, Chunquiao; Bloss, Jeffrey D; Moore, David H; Long, Harry J.

Am J Obstet Gynecol ; 199(5): 539.e1-6, 2008 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-18565487

13.

Secondary surgical cytoreduction for advanced ovarian carcinoma.

Rose, Peter G; Nerenstone, Stacy; Brady, Mark F; Clarke-Pearson, Daniel; Olt, George; Rubin, Stephen C; Moore, David H; Small, James M.

N Engl J Med ; 351(24): 2489-97, 2004 Dec 09.

Artigo em Inglês | MEDLINE | ID: mdl-15590951

14.

Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology's Clinical Practice Robotics Task Force.

Ramirez, Pedro T; Adams, Sarah; Boggess, John F; Burke, William M; Frumovitz, Michael M; Gardner, Ginger J; Havrilesky, Laura J; Holloway, Robert; Lowe, M Patrick; Magrina, Javier F; Moore, David H; Soliman, Pamela T; Yap, Stephanie.

Gynecol Oncol ; 124(2): 180-4, 2012 Feb.

Artigo em Inglês | MEDLINE | ID: mdl-22079679

15.

Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study.

Lanciano, Rachelle; Calkins, Alison; Bundy, Brian N; Parham, Groesbeck; Lucci, Joseph A; Moore, David H; Monk, Bradley J; O'Connor, Dennis M.

J Clin Oncol ; 23(33): 8289-95, 2005 Nov 20.

Artigo em Inglês | MEDLINE | ID: mdl-16230678

16.

Cervical cancer.

Moore, David H.

Obstet Gynecol ; 107(5): 1152-61, 2006 May.

Artigo em Inglês | MEDLINE | ID: mdl-16648423

17.

ACR Appropriateness Criteria® Management of Recurrent Endometrial Cancer.

Elshaikh, Mohamed A; Vance, Sean; Gaffney, David K; Biagioli, Matthew; Jhingran, Anuja; Jolly, Shruti; Kidd, Elizabeth; Lee, Larissa J; Li, Linna; Moore, David H; Rao, Gautam G; Wahl, Andrew O; Williams, Ned L; Yashar, Catheryn M; Small, William.

Am J Clin Oncol ; 39(5): 507-15, 2016 10.

Artigo em Inglês | MEDLINE | ID: mdl-27400117

18.

Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Morris, Mitchell; Blessing, John A; Monk, Bradley J; McGehee, Ramon; Moore, David H.

J Clin Oncol ; 22(16): 3340-4, 2004 Aug 15.

Artigo em Inglês | MEDLINE | ID: mdl-15310778

19.

Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.

Moore, David H; Donnelly, James; McGuire, William P; Almadrones, Lois; Cella, David F; Herzog, Thomas J; Waggoner, Steven E.

J Clin Oncol ; 21(22): 4207-13, 2003 Nov 15.

Artigo em Inglês | MEDLINE | ID: mdl-14615449

20.

Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Moore, David H; Blessing, John A; McQuellon, Richard P; Thaler, Howard T; Cella, David; Benda, Jo; Miller, David S; Olt, George; King, Stephanie; Boggess, John F; Rocereto, Thomas F.

J Clin Oncol ; 22(15): 3113-9, 2004 Aug 01.

Artigo em Inglês | MEDLINE | ID: mdl-15284262

Biblioteca Virtual em Saúde

Saúde Pública Brasil

Sua seleção (0)

Formato de exportação:

Exportar:

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.

ACR Appropriateness Criteria® Adjuvant Management of Early-Stage Endometrial Cancer.

ACR Appropriateness Criteria® Adjuvant Therapy in Vulvar Cancer.

Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study.

A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study.

Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.

Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).

Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one?

Reflections on vulvar tumors, lymphatic drainage, and sentinel lymph node biopsy.

Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies.

Secondary surgical cytoreduction for advanced ovarian carcinoma.

Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology's Clinical Practice Robotics Task Force.

Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study.

Cervical cancer.

ACR Appropriateness Criteria® Management of Recurrent Endometrial Cancer.

Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.

Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.